Neoleukin Therapeutics Announces Additions to Management Team
19 September 2019 - 10:00PM
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a
biopharmaceutical company utilizing sophisticated computational
methods to design de novo protein therapeutics,
today announced the appointments of Leslie Aberman as Vice
President, Legal Affairs and Intellectual Property, and Samantha
Willing, Vice President, People.
“We are delighted to have Leslie and Sam join Neoleukin and
believe they will make significant impacts as leaders and strategic
thinkers as we continue to grow our team and our scientific
expertise,” said Jonathan Drachman, M.D., Chief Executive Officer
of Neoleukin.
Leslie Aberman brings over 18 years of law firm and
biopharmaceutical experience. She previously served as Associate
General Counsel for the Infectious Disease Research Institute and
provided intellectual property guidance at Seattle Genetics from
2007 to 2015, most recently as Senior Director, Intellecutal
Property. She previously served in the life sciences practice group
at Woodcock Washburn, LLP and Kilpatrick Townsend and Stockton,
LLP. Aberman received a J.D. from Columbia University School of Law
and a B.S. in Biochemistry from Brown University.
Samantha Willing brings over 20 years of human resources
experience spanning the hospitality, hi-tech and biotech
industries. This includes roles at Limeade, a Bellevue-based
technology company, Seattle Genetics, and Microsoft. In addition,
Willing has operated an executive coaching business for 10 years
and studied Business and Human Resources at Washington State
University.
About Neoleukin Therapeutics, Inc.Neoleukin is
a biopharmaceutical company creating next generation
immunotherapies using de novo protein design
technology. Neoleukin uses sophisticated computational
methods to design proteins that demonstrate specific pharmaceutical
properties that provide potentially superior therapeutic benefit
over native proteins. Neoleukin’s lead product candidate,
NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate
alpha receptor binding. For more information, please visit the
Neoleukin website: www.neoleukin.com.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian
Korb646-378-2923bkorb@troutgroup.com
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Apr 2024 to May 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From May 2023 to May 2024